One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Aducanumab and the Business of Alzheimer Disease—Some Choice
Jason Karlawish, MD1,2
doi : 10.1001/jamaneurol.2021.3123
JAMA Neurol. 2021;78(11):1303-1304
What the Aducanumab Approval Reveals About Alzheimer Disease Research
Jennifer J. Manly, PhD1; M. Maria Glymour, ScD2
doi : 10.1001/jamaneurol.2021.3404
JAMA Neurol. 2021;78(11):1305-1306
US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
Vincent Planche, MD, PhD1,2; Nicolas Villain, MD, PhD3,4
doi : 10.1001/jamaneurol.2021.3126
JAMA Neurol. 2021;78(11):1307-1308
I Only Want to See You—A Challenge of Long-term Clinician-Patient Relationships in Team-Based Clinical Care
Jeffrey H. Millstein, MD1
doi : 10.1001/jamaneurol.2021.3029
JAMA Neurol. 2021;78(11):1309-1310
Methylphenidate for Apathy in Alzheimer Disease—Why Should We Care?
Carolyn Fredericks, MD1
doi : 10.1001/jamaneurol.2021.2942
JAMA Neurol. 2021;78(11):1311-1313
Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
Mayte Sánchez van Kammen, MD1; Diana Aguiar de Sousa, MD, PhD2; Sven Poli, MD, MSc3,4; Charlotte Cordonnier, MD, PhD5; Mirjam R. Heldner, MD, MSc6; Anita van de Munckhof, MD1; Katarzyna Krzywicka, MD, MPhil1; Thijs van Haaps, BSc7; Alfonso Ciccone, MD, PhD8; Saskia Middeldorp, MD, PhD9; Marcel M. Levi, MD, PhD10; Johanna A. Kremer Hovinga, MD11; Suzanne Silvis, MD, PhD12; Sini Hiltunen, MD, PhD13; Maryam Mansour, MD14; Antonio Arauz, MD, PhD15; Miguel A. Barboza, MD, MSc16; Thalia S. Field, MD, MHSc17; Georgios Tsivgoulis, MD, PhD18; Simon Nagel, MD19; Erik Lindgren, MD20,21; Turgut Tatlisumak, MD, PhD20,21; Katarina Jood, MD, PhD20,21; Jukka Putaala, MD, PhD13; Jose M. Ferro, MD, PhD2; Marcel Arnold, MD6; Jonathan M. Coutinho, MD, PhD1; and the Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study Group
doi : 10.1001/jamaneurol.2021.3619
JAMA Neurol. 2021;78(11):1314-1323
Thrombosis with thrombocytopenia syndrome (TTS) has been reported after vaccination with the SARS-CoV-2 vaccines ChAdOx1 nCov-19 (Oxford–AstraZeneca) and Ad26.COV2.S (Janssen/Johnson & Johnson).
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease
Jacobo Mintzer, MD, MBA1; Krista L. Lanctôt, PhD2; Roberta W. Scherer, PhD3; Paul B. Rosenberg, MD4; Nathan Herrmann, MD2; Christopher H. van Dyck, MD5; Prasad R. Padala, MD6; Olga Brawman-Mintzer, MD1; Anton P. Porsteinsson, MD7; Alan J. Lerner, MD8; Suzanne Craft, PhD9; Allan I. Levey, MD, PhD10; William Burke, MD11; Jamie Perin, PhD3; David Shade, JD3; for the ADMET 2 Research Group
doi : 10.1001/jamaneurol.2021.3356
JAMA Neurol. 2021;78(11):1324-1332
Apathy, characterized by diminished will or initiative and one of the most prevalent neuropsychiatric symptoms in individuals with Alzheimer disease, is associated with significant caregiver burden, excess disability, increased medical costs, and mortality.
Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis
Margherita Nosadini, MD, PhD1,2; Michael Eyre, MD3,4; Erika Molteni, PhD3,5; Terrence Thomas, MD6; Sarosh R. Irani, MD, PhD7,8; Josep Dalmau, MD, PhD9,10,11; Russell C. Dale, MD, PhD12; Ming Lim, MD, PhD4,13; and the International NMDAR Antibody Encephalitis Consensus Group
doi : 10.1001/jamaneurol.2021.3188
JAMA Neurol. 2021;78(11):1333-1344
Overall, immunotherapy has been shown to improve outcomes and reduce relapses in individuals with N-methyl-d-aspartate receptor (NMDAR) antibody encephalitis (NMDARE); however, the superiority of specific treatments and combinations remains unclear.
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity
Keith Vossel, MD, MSc1,2,3,4,5; Kamalini G. Ranasinghe, MBBS, PhD1; Alexander J. Beagle, MD1; Alice La, PharmD1; Kasey Ah Pook, BS2; Madelyn Castro, BS2; Danielle Mizuiri, BS6; Susanne M. Honma, BS6; Nisha Venkateswaran, BA2,4; Mary Koestler, PhD1; Wenbo Zhang, MD7,8; Lennart Mucke, MD1,5; Michael J. Howell, MD8; Katherine L. Possin, PhD1; Joel H. Kramer, PhD1; Adam L. Boxer, MD, PhD1; Bruce L. Miller, MD1; Srikantan S. Nagarajan, PhD6; Heidi E. Kirsch, MD, MS6,9
doi : 10.1001/jamaneurol.2021.3310
JAMA Neurol. 2021;78(11):1345-1354
Network hyperexcitability may contribute to cognitive dysfunction in patients with Alzheimer disease (AD).
Detection of Neoplasms by Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid
Wei Gu, MD, PhD1,2; Andreas M. Rauschecker, MD, PhD3; Elaine Hsu, BS1; Kelsey C. Zorn, BA, MHS4; Yasemin Sucu, BS1; Scot Federman, BA1; Allan Gopez, BS1; Shaun Arevalo, BS1; Hannah A. Sample, BS4; Eric Talevich, PhD5; Eric D. Nguyen, MD, PhD1; Marc Gottschall, BS1; Bardia Nourbakhsh, MD, MAS6; Carl A. Gold, MD, MS7; Bruce A. C. Cree, MD, PhD, MAS8; Vanja C. Douglas, MD8; Megan B. Richie, MD8; Maulik P. Shah, MD, MHS8; S. Andrew Josephson, MD8,9; Jeffrey M. Gelfand, MD, MAS8; Steve Miller, MD, PhD1; Linlin Wang, MD1; Tarik Tihan, MD, PhD10; Joseph L. DeRisi, PhD4,11; Charles Y. Chiu, MD, PhD12,13; Michael R. Wilson, MD, MAS8
doi : 10.1001/jamaneurol.2021.3088
JAMA Neurol. 2021;78(11):1355-1366
Cerebrospinal fluid (CSF) cytologic testing and flow cytometry are insensitive for diagnosing neoplasms of the central nervous system (CNS). Such clinical phenotypes can mimic infectious and autoimmune causes of meningoencephalitis.
Association of Enzyme-Inducing Antiseizure Drug Use With Long-term Cardiovascular Disease
Colin B. Josephson, MD, MSc1,2,3,4,5; Samuel Wiebe, MD, MSc1,2,3,4,6; Guillermo Delgado-Garcia, MD, MSc1; Arturo Gonzalez-Izquierdo, PhD7,8; Spiros Denaxas, PhD7,8,9; Tolulope T. Sajobi, PhD1,2,3,4; Mubasiru Lamidi, MSc2; Meng Wang, MSc2; Mark R. Keezer, MDCM, PhD10
doi : 10.1001/jamaneurol.2021.3424
JAMA Neurol. 2021;78(11):1367-1374
Enzyme-inducing antiseizure medications (eiASMs) have been hypothesized to be associated with long-term risks of cardiovascular disease.
Head-to-Head Comparison of 8 Plasma Amyloid-? 42/40 Assays in Alzheimer Disease
Shorena Janelidze, PhD1; Charlotte E. Teunissen, PhD2; Henrik Zetterberg, MD, PhD3,4,5,6; José Antonio Allué, PhD7; Leticia Sarasa, PhD7; Udo Eichenlaub, PhD8; Tobias Bittner, PhD9; Vitaliy Ovod, MSs10; Inge M. W. Verberk, MSs2; Kenji Toba, MD, PhD11,12; Akinori Nakamura, MD, PhD13; Randall J. Bateman, MD, PhD10; Kaj Blennow, MD, PhD4,14; Oskar Hansson, MD, PhD1,15
doi : 10.1001/jamaneurol.2021.3180
JAMA Neurol. 2021;78(11):1375-1382
Blood-based tests for brain amyloid-? (A?) pathology are needed for widespread implementation of Alzheimer disease (AD) biomarkers in clinical care and to facilitate patient screening and monitoring of treatment responses in clinical trials.
Discerning the Role of Autoimmunity and Autoantibodies in Epilepsy
Claude Steriade, MD1; Lisa Gillinder, MBBS2,3; Kirsty Rickett, MInfoTech-Librarianship3; Gunter Hartel, PhD4; Lindsay Higdon, MD5; Jeffrey Britton, MD6; Jacqueline French, MD1
doi : 10.1001/jamaneurol.2021.3113
JAMA Neurol. 2021;78(11):1383-1390
The literature on neural autoantibody positivity in epilepsy has expanded over the last decade, with an increased interest among clinicians in identifying potentially treatable causes of otherwise refractory seizures.
Carcinomatosis Encephalitis Secondary to Neuroendocrine Transformation of Prostate Cancer
Alexandria Ellen Melendez-Zaidi, MD, PhD1; Alexander Ou, MD2; Gregory N. Fuller, MD3
doi : 10.1001/jamaneurol.2021.3304
JAMA Neurol. 2021;78(11):1391-1392
Multiple Facial Ulcers Following a Stroke
Beke Esther Linnemann1; Alexander Neumann, MD2; Iakov Shimanovich, MD1
doi : 10.1001/jamaneurol.2021.2236
JAMA Neurol. 2021;78(11):1393-1394
Statewide Emergency Medical Services Protocols for Suspected Stroke and Large Vessel Occlusion
Carlin C. Chuck, BS1; Thomas J. Martin, BA, NRP1; Roshini Kalagara, BA2; Tracy E. Madsen, MD, PhD3; Karen L. Furie, MD4; Shadi Yaghi, MD4; Michael E. Reznik, MD4
doi : 10.1001/jamaneurol.2021.3227
JAMA Neurol. 2021;78(11):1404-1406
Plasma Biomarkers of Tau and Neurodegeneration During Major Cardiac and Noncardiac Surgery
Igor Feinstein, MD, PhD1; Edward N. Wilson, PhD2; Michelle S. Swarovski, BS2; Katrin I. Andreasson, MD2; Martin S. Angst, MD1; Michael D. Greicius, MD, MPH2
doi : 10.1001/jamaneurol.2021.2823
JAMA Neurol. 2021;78(11):1407-1409
Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2
Shirley Shapiro Ben David, MD1; Israel Potasman, MD2; Daniella Rahamim-Cohen, MD1
doi : 10.1001/jamaneurol.2021.3287
JAMA Neurol. 2021;78(11):1409-1411
Traumatic Brain Injury Recovery Trajectories in Patients With Disorders of Consciousness
Michael C. Smith, MD1; Mayur B. Patel, MD, MPH1; Oscar D. Guillamondegui, MD, MPH1
doi : 10.1001/jamaneurol.2021.3433
JAMA Neurol. 2021;78(11):1411
Traumatic Brain Injury Recovery Trajectories in Patients With Disorders of Consciousness
Hisse Arnts, MD1; Willemijn S. van Erp, MD, PhD2; Pepijn van den Munckhof, MD, PhD1
doi : 10.1001/jamaneurol.2021.3436
JAMA Neurol. 2021;78(11):1412
Traumatic Brain Injury Recovery Trajectories in Patients With Disorders of Consciousness—Reply
Robert G. Kowalski, MBBCh, MS1,2; John Whyte, MD, PhD3; Joseph T. Giacino, PhD4
doi : 10.1001/jamaneurol.2021.3430
JAMA Neurol. 2021;78(11):1412-1413
